Common Blood Marker CEA Predicts Outcomes in Prostate Cancer Radioligand Therapy
A prospective study of 142 patients finds that elevated baseline CEA independently predicts shorter survival in men with metastatic castration-resistant ...
A prospective study of 142 patients finds that elevated baseline CEA independently predicts shorter survival in men with metastatic castration-resistant ...
A prospective imaging study shows that radium-223 significantly reduces PD-L1 expression and depletes immune cells in prostate cancer bone metastases, ...
UCLA researchers have identified a way to make antibody-drug conjugates more powerful against metastatic castration-resistant prostate cancer, an advanced form ...
A simple blood test may soon help clinicians manage metastatic castration-resistant prostate cancer (mCRPC) more precisely, according to a study ...
In a groundbreaking study published in "Advances in Therapy," researchers have taken a detailed look at the intricate landscape of ...
Lutetium-177-PSMA-617 (Pluvicto®) has emerged as a groundbreaking radiolabeled therapeutic agent in the battle against advanced prostate cancer, specifically targeting metastatic ...
In recent advancements in the field of oncology, a study led by Deng, Chen, and Zhong has unveiled a significant ...
Prostate cancer persists as a formidable global health adversary, ranking as the second most prevalent malignancy in men worldwide. While ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine